Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/15
End: 11/30/26
Due: 11/30/27
Phase: N/A
Priority: Normal
Start: 04/30/14
End: 02/28/15
Due: 02/28/16
Phase: N/A
Priority: Normal
Start: 12/20/19
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 05/07/19
End: 06/30/24
Due: 06/30/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease | NCT02402660 | Alkeus Pharmaceuticals, Inc. | user2@example.com | None | 2015-08-31 | 2026-11-30 | 2027-11-30 | - | - | 2025-07-14 |
| Phase 1 Safety Study of ALK-001 in Healthy Volunteers | NCT02230228 | Alkeus Pharmaceuticals, Inc. | user2@example.com | None | 2014-04-30 | 2015-02-28 | 2016-02-28 | - | - | 2025-07-14 |
| Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) | NCT04239625 | Alkeus Pharmaceuticals, Inc. | user2@example.com | None | 2019-12-20 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |
| Phase 3 Study of ALK-001 in Geographic Atrophy | NCT03845582 | Alkeus Pharmaceuticals, Inc. | user2@example.com | None | 2019-05-07 | 2024-06-30 | 2025-06-30 | - | - | 2025-07-14 |